Identity
TRH — thyrotropin-releasing hormone, sold in synthetic drug form as protirelin — is the smallest of the hypothalamic releasing hormones, a tripeptide (pGlu-His-Pro-NH2). It sits at the top of the thyroid axis, and it is the same molecule the hypothalamus makes.
Mechanism (as proposed / established)
TRH's classic role is endocrine: released by the hypothalamus, it drives the pituitary to secrete thyroid-stimulating hormone (TSH) and prolactin, and TSH in turn drives the thyroid. That cascade is textbook. Less widely appreciated is that TRH also has direct central-nervous-system actions — arousal, an analeptic (stimulant-like) effect, and neuroprotective signals — that are independent of the thyroid and are the reason it drew neurological interest.
The approved reality, and the undeveloped CNS story
As a medicine, protirelin's approved use is diagnostic: the TRH stimulation test, which measures the pituitary's TSH response and was historically important in thyroid and pituitary evaluation. Modern highly sensitive TSH assays made the test largely unnecessary, so its clinical use has declined.
The CNS side is a genuine but unfinished story. TRH's direct brain effects were explored in depression, spinal cord injury, ALS and disorders of consciousness — real research, mostly older, small or preclinical. It never converged on an approved neurological therapy, defeated largely by a very short half-life and limited access to the brain. That is the honest context for any "nootropic" or "energy" framing encountered in research channels: the pharmacology is real, the development stalled, and the casual use is not a validated protocol.